Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00093145
Status:
COMPLETED
Last Update Posted:
2019-11-25
First Post:
2004-10-04
Brief Title:
Study of Albumin-bound Paclitaxel Abraxane in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
Sponsor:
Celgene
Organization:
Celgene
Study Overview
Official Title:
A Phase II Study of Weekly Dose-Dense Nanoparticle Paclitaxel ABI-007 Carboplatin With Herceptin As First-Line Therapy of Advanced HER-2 Positive Breast Cancer
Status:
COMPLETED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will treat patients with advanced breast cancer with a new anti-cancer medicine used in combination with two existing anti-cancer medications Albumin-bound paclitaxel ABI-007 Carboplatin and Herceptin Participants will be given the combination therapy on a weekly basis and may continue on therapy as long as their condition improves and drug toxicity is tolerated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None